Please assess the completion status of the following clinical trial:

Trial Title: Estradiol Levels in Patients Treated With Estring

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Stage I-III estrogen receptor positive breast cancer (positive for estrogen receptor (ER)) with positivity defined as immunohistochemical staining in ≥ 10% of cells) on adjuvant hormonal therapy with aromatase inhibitors (anastrozole, letrozole or exemestane)~* Adults over 18 years of age with a life expectancy of at least 3 months~* Attained menopause as defined by World Health Organization Criteria (defined as permanent cessation of menstruation resulting from the loss of ovarian follicular activity. This is recognized to occur after 12 consecutive months of amenorrhea, for which there is no other obvious pathological or physiological cause.)~* Persistent genitourinary symptoms causing discomfort for more than 2 weeks prior to the visit with the physician.~* Tried at least 1 prior pharmacological/ non-pharmacological treatment for their genitourinary symptoms~* Be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to any study specific procedures~* Be willing and able to comply with the treatment plan, scheduled clinic visits, laboratory tests and other study procedures~Exclusion Criteria:~* Patients with metastatic breast cancer~* Have a concurrent active non-breast malignancy except for non-melanoma skin cancer~* Patients with vaginal stenosis~* Patients unable to apply Estring

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Estradiol (Type: EXPERIMENTAL): ESTRING® (estradiol vaginal ring) is a slightly opaque ring with a whitish core containing a drug reservoir of 2 mg estradiol. Estradiol, silicone polymers and barium sulfate are combined to form the ring. When placed in the vagina, ESTRING releases estradiol, approximately 7.5 mcg per 24 hours, in a consistent stable manner over 90 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).